## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary)

SHEET 1 OF 1

 Application No.
 10/785446

 Filing Date
 February 23, 2004

 First Named Inventor
 Lauren Otsuki

 Art Unit
 1614

 Examiner
 Leslie A. Royds

 Attorney Docket No.
 NOCAR 007A

Examiner Initials Cite Number - Kind Code (if known) Example: 1,234,667 B1 Publication Date MM-DD-YYYY Name of Patentee or Applicant Figures Appear

FOREIGN PATENT DOCUMENTS							
Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T¹		
		-					
		Country Code-Number-Kind Code	Cite Foreign Patent Document Publication Country Code-Number-Kind Code Date	Cite Foreign Patent Document Publication Country Code-Number-Kind Code Date Name of Patentee or	Cite Foreign Patent Document Publication Name of Patentee or Where Relevant Passages or Where Relevant Passages or		

Examiner Cite Initials No.			
	2.	Schoolwerth, et al. "Renal Considerations in Angiotensin Converting Enzyme Inhibitor Therapy." Circulation. 104:1985-1991 (2001).	
	2.	Wilkinson, Robert. "β-Blockers and Renal Function." Drugs. 23:195-206 (1982).	
	_	T	

3907000 sma062007

	Examiner Signature	Date Considered			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

T1 - Place a check mark in this area when an English language Translation is attached.